GLFD Guilford Pharmaceuticals (MM)

Guilford Pharmaceuticals to Announce Year-End 2003 Financial Results on Tuesday, February 17, 2004 BALTIMORE, Feb. 9 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. will announce its year-end 2003 financial results on Tuesday, February 17, 2004 before the opening of the U.S. financial markets. The company will also host a conference call and live audio webcast at 11:00 a.m. E.S.T. following the announcement. During this call, Guilford's management will discuss the financial results and other business for the upcoming year. The press release and live webcast can be accessed by going to the Investor Relations section of Guilford's website at http://www.guilfordpharm.com/. Following the webcast, an archived version of the call will be available until February 19, 2004. To participate in the live conference call, U.S. residents should dial 1-800-901-5241, international callers 617-786-2963. The participant passcode is 18159832. An audio replay of the conference call will be availablefor 48 hours beginning at approximately 1:00 p.m. E.S.T. on February 17, 2004 through 1:00 p.m. February 19, 2004. To access the replay, U.S. residents should dial 888- 286-8010, (int'l callers 617-801-6888), passcode 11020980. Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and post-prostatectomy erectile dysfunction. Contact: Guilford Pharmaceuticals Inc. Stacey Jurchison 410.631.5022 DATASOURCE: Guilford Pharmaceuticals Inc. CONTACT: Stacey Jurchison, Guilford Pharmaceuticals, +1-410-631-5022, Web site: http://www.guilfordpharm.com/ Company News On-Call: http://www.prnewswire.com/comp/112882.html

Copyright